Veopoz Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of complement-mediated diseases, availability of monoclonal antibody engineering platforms, expansion of orphan drug development programs, increased diagnosis of ultra-rare immune disorders, supportive regulatory incentives for rare disease therapies.

The growth in the forecast period can be attributed to expansion of personalized immunotherapy approaches, rising investments in complement biology research, growing adoption of precision medicine in rare diseases, increasing healthcare spending on orphan drugs, advancement of next-generation biologics manufacturing. Major trends in the forecast period include expanding use of complement inhibitors in rare diseases, growing focus on targeted monoclonal antibody therapies, increasing clinical emphasis on complement pathway modulation, rising adoption of precision diagnostics for rare disorders, strengthening regulatory support for orphan drugs.

The increasing demand for personalized medicine is expected to drive the growth of the Veopoz market in the coming years. Personalized medicine, also known as precision medicine, tailors treatments and healthcare decisions to the individual characteristics of each patient. The rising demand is driven by advancements in genomics and biotechnology, which enable more targeted and effective therapies that improve patient outcomes and reduce side effects. Veopoz (Pozelimab-bbfg) acts as a personalized medicine by selectively inhibiting complement factor C5 activation, allowing treatments to be customized based on a patient’s genetic profile, disease severity, and individual characteristics in complement-mediated conditions. For example, according to the Personalized Medicine Coalition (PMC), a US-based healthcare organization, personalized medicines accounted for over one-third of FDA drug approvals in 2023 for the fourth consecutive year, including 16 new treatments for rare diseases - more than double the six approved in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the Veopoz market.

A key trend in the Veopoz market is the expansion of approved indications to broaden therapeutic applications and increase market reach. Expanding indications allows the company to serve a larger patient population and strengthen its position in the biologics and immunology sectors. For instance, in August 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received FDA approval for Veopoz as the first treatment for CHAPLE disease, an ultra-rare hereditary disorder affecting both adults and children aged one year and older. Veopoz is a fully human monoclonal antibody designed to target complement factor C5, regulating an overactive immune response. This approval represents a significant milestone for Regeneron, marking their tenth FDA-approved therapy and addressing pre-approval inspection issues from another product.

In August 2023, Regeneron Pharmaceuticals partnered with Orsini Specialty Pharmacy, designating Orsini as the exclusive specialty pharmacy for Veopoz. This partnership enables Orsini to support patients with ultra-rare conditions by providing access to a life-changing therapy previously unavailable. Orsini Specialty Pharmacy is a US-based independent specialty pharmacy focused on rare diseases and gene therapies.

Major companies operating in the veopoz market are Regeneron Pharmaceuticals Inc.

North America was the largest region in the veopoz market in 2025. The regions covered in the veopoz market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veopoz market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the veopoz market by increasing costs associated with imported biologic raw materials, specialized reagents, single-use bioprocessing equipment, and cold-chain logistics components required for monoclonal antibody production and distribution. Manufacturing operations in North America and Europe are most affected due to reliance on cross-border sourcing of high-purity inputs, while Asia-Pacific faces cost pressure on biologics export logistics. These tariffs are increasing overall production and distribution costs, potentially affecting pricing strategies and hospital procurement budgets. However, they are also encouraging localized biologics manufacturing, regional supply chain diversification, and long-term investment in domestic biopharmaceutical production capabilities.

The veopoz market research report is one of a series of new reports that provides veopoz market statistics, including veopoz industry global market size, regional shares, competitors with a veopoz market share, detailed veopoz market segments, market trends and opportunities, and any further data you may need to thrive in the veopoz industry. This veopoz market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veopoz (pozelimab-bbfg) is a human monoclonal IgG4 antibody that selectively targets and inhibits complement factor C5 in the complement pathway. It helps regulate immune responses in diseases where complement dysregulation is involved, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). This targeted action aims to reduce tissue damage and improve outcomes in these rare and ultra-rare conditions.

The primary indications for Veopoz are gastrointestinal symptoms, hypoalbuminemia, edema, hypogammaglobulinemia, and malnutrition. Gastrointestinal symptoms include signs or conditions affecting the digestive system, such as nausea, vomiting, diarrhea, or abdominal pain. Veopoz is used to manage gastrointestinal symptoms in patients with conditions like short bowel syndrome. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving both adult and pediatric patients.

The veopoz market consists of sales of Veopoz (pozelimab) injection and companion medications for autoimmune diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.